149 related articles for article (PubMed ID: 28250535)
1. An antibiotic's journey from marketing authorization to use, Norway.
Årdal C; Blix HS; Plahte J; Røttingen JA
Bull World Health Organ; 2017 Mar; 95(3):220-226. PubMed ID: 28250535
[TBL] [Abstract][Full Text] [Related]
2. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
3. Preserving the 'commons': addressing the sustainable use of antibiotics through an economic lens.
Morel CM; Edwards SE; Harbarth S
Clin Microbiol Infect; 2017 Oct; 23(10):718-722. PubMed ID: 28811243
[TBL] [Abstract][Full Text] [Related]
4. ["Look to Norway"--but for how long?].
Haug JB; Raastad R; Berild D
Tidsskr Nor Laegeforen; 2010 Aug; 130(15):1484-6. PubMed ID: 20706311
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic guidelines lead to reductions in the use and cost of antibiotics in a university hospital.
Berild D; Ringertz SH; Lelek M; Fosse B
Scand J Infect Dis; 2001; 33(1):63-7. PubMed ID: 11234982
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of drug use evaluation and antibiotic authorization on patients' clinical outcomes, antibiotic consumption, and antibiotic expenditures.
Rattanaumpawan P; Sutha P; Thamlikitkul V
Am J Infect Control; 2010 Feb; 38(1):38-43. PubMed ID: 19699014
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic policy.
Gyssens IC
Int J Antimicrob Agents; 2011 Dec; 38 Suppl():11-20. PubMed ID: 22018989
[TBL] [Abstract][Full Text] [Related]
8. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
[TBL] [Abstract][Full Text] [Related]
9. [Optimizing antibiotics use policy in the Netherlands. I. The Netherlands Antibiotics Policy Foundation (SWAB)].
van Kasteren ME; Wijnands WJ; Stobberingh EE; Janknegt R; Verbrugh HA; van der Meer JW
Ned Tijdschr Geneeskd; 1998 Apr; 142(17):949-51. PubMed ID: 9623167
[TBL] [Abstract][Full Text] [Related]
10. Changes in antibiotic use, cost and consumption after an antibiotic restriction policy applied by infectious disease specialists.
Ozkurt Z; Erol S; Kadanali A; Ertek M; Ozden K; Tasyaran MA
Jpn J Infect Dis; 2005 Dec; 58(6):338-43. PubMed ID: 16377863
[TBL] [Abstract][Full Text] [Related]
11. [Rational use of antibiotics in hospitals].
Berild D; Haug JB
Tidsskr Nor Laegeforen; 2008 Oct; 128(20):2335-9. PubMed ID: 19096490
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial stewardship: bridging the gap between quality care and cost.
Goff DA
Curr Opin Infect Dis; 2011 Feb; 24 Suppl 1():S11-20. PubMed ID: 21200180
[TBL] [Abstract][Full Text] [Related]
13. Economics of antibiotic resistance.
Sipahi OR
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):523-39. PubMed ID: 18662118
[TBL] [Abstract][Full Text] [Related]
14. An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia's public sector: Findings and therapeutic implications.
Kibuule D; Mubita M; Naikaku E; Kalemeera F; Godman BB; Sagwa E
Int J Clin Pract; 2017 Feb; 71(2):. PubMed ID: 28090718
[TBL] [Abstract][Full Text] [Related]
15. Inventory of antibiotic stewardship programs in general practice in France and abroad.
Wang S; Pulcini C; Rabaud C; Boivin JM; Birgé J
Med Mal Infect; 2015 Apr; 45(4):111-23. PubMed ID: 25747501
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches are needed to develop tomorrow's antibacterial therapies.
Spellberg B; Bartlett J; Wunderink R; Gilbert DN
Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic Prescribing among Pediatric Inpatients with Potential Infections in Two Private Sector Hospitals in Central India.
Sharma M; Damlin A; Pathak A; Stålsby Lundborg C
PLoS One; 2015; 10(11):e0142317. PubMed ID: 26540104
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic prescribing practice for acute, uncomplicated respiratory tract infections in primary care settings in New Delhi, India.
Kotwani A; Holloway K
Trop Med Int Health; 2014 Jul; 19(7):761-8. PubMed ID: 24750565
[TBL] [Abstract][Full Text] [Related]
19. Impact of antibiotic restrictions: the pharmaceutical perspective.
Power E
Clin Microbiol Infect; 2006 Aug; 12 Suppl 5():25-34. PubMed ID: 16827822
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry.
Lavin BS
Infect Control Hosp Epidemiol; 2000 Jan; 21(1 Suppl):S32-5. PubMed ID: 10654633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
